Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients

Diabetes Research and Clinical Practice

Volumn 86, Issue 1, 2009, Pages 44-50

  Kiyici, Sinem ^a   Ersoy, Canan ^a   Kaderli, Aysel ^a   Fazlioglu, Murat ^a   Budak, Ferah ^a   Duran, Cevdet ^b   Oz Gul, Ozen ^a   Sigirli, Deniz ^a   Baran, Ibrahim ^a   Tuncel, Ercan ^a   Erturk, Erdinc ^a   Imamoglu, Sazi ^a  

^a ULUDAG UNIVERSITY   (Turkey)

^b Konya Education and Research Hospital   (Turkey)

Author keywords

Arterial stiffness; MCP 1; Metformin; MMP 9; Rosiglitazone

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; ROSIGLITAZONE;

ADULT; AGED; ARTERIAL STIFFNESS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DIETARY INTAKE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MECHANISM; DRUG RESPONSE; ELASTICITY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; LONG TERM CARE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MATRIX METALLOPROTEINASE 9; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; VASCULAR RESISTANCE;

EID: 69849104827     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2009.07.004     Document Type: Article

References (35)

1. Lim S.C., Caballero A.E., Smakowski P., LoGerfo F.W., Horton E.S., and Veves A. Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria. Diabetes Care 22 (1999) 1865-1870
2. Grey E., Bratteli C., Glasser S.P., Alinder C., Finkelstein S.M., Lindgren B.R., et al. Reduced small artery but not large artery elasticity is an independent risk marker for cardiovascular events. Am. J. Hypertens. 16 4 (2003) 265-269
3. Correia M.L., and Haynes W.G. Arterial compliance and endothelial function. Curr. Diab. Rep. 7 (2007) 269-277
4. Nigam A., Mitchell G.F., Lambert J., and Tardif J.C. Relation between conduit vessel stiffness (assessed by tonometry) and endothelial function (assessed by flow-mediated dilatation) in patients with and without coronary heart disease. Am. J. Cardiol. 92 (2003) 395-399
5. Fitch R.M., Vergona R., Sullivan M.E., and Wang Y.X. Nitric oxide synthase inhibition increases aortic stiffness measured by pulse wave velocity in rats. Cardiovasc. Res. 51 (2001) 351-358
6. Henry R.M., Ferreira I., Kostense P.J., Dekker J.M., Nijpels G., Heine R.J., et al. Type 2 diabetes is associated with impaired endothelium-dependent, flow mediated dilation, but impaired glucose metabolism is not; the Hoorn study. Atherosclerosis 174 (2004) 49-56
7. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90 (2002) 251-262
8. Mine S., Okada Y., Tanikawa T., Kawahara C., Tabata T., and Tanaka Y. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem. Biophys. Res. Commun. 344 3 (2006) 780-785
9. de Lemos J.A., Morrow D.A., Sabatine M.S., Murphy S.A., Gibson C.M., Antman E.M., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107 5 (2003) 690-695
10. Dandona P., Ghanim H., Chaudhuri A., and Mohanty P. Thiazolidinediones-improving endothelial function and potential long-term benefits on cardiovascular disease in subjects with type 2 diabetes. Diabetes Complications 22 1 (2008) 62-75
11. Turner R.C., Holman R.R., Stratton I.M., Cull C.A., Matthews D.R., Manley S.E., et al. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 854-865
12. Caballero A.E., Delgado A., Aguilar-Salinas C.A., Herrera A.N., Castillo J.L., Cabrera T., et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab. 89 8 (2004) 3943-3948
13. De Jager J., Kooy A., Lehert P., Bets D., Wulffelé M.G., Teerlink T., et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J. Intern. Med. 257 1 (2005) 100-109
14. Mashavi M., Hanah R., Boaz M., Gavish D., Matas Z., Fux A., et al. Effect of homocysteine-lowering therapy on arterial elasticity and metabolic parameters in metformin-treated diabetic patients. Atherosclerosis 199 2 (2008) 362-367
15. American Diabetes Association, Position statement: standarts of medical care in diabetes-2006, Diabetes Care, 29 (supp1) (2006) 4-34.
16. Cohn J.N., Finkelstein S., McVeigh G., Morgan D., LeMay L., Robinson J., et al. Noninvasive pulse wave analysis for the early detection of vascular disease. Hypertension 26 3 (1995) 503-508
17. Shargorodsky M., Michaelova K., Boaz M., Gavish D., and Zimlichman R. Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study. Diabet. Med. 24 11 (2007) 1254-1260
18. Syeda B., Gottsauner-Wolf M., Denk S., Pichler P., Khorsand A., and Glogar D. Arterial compliance: a diagnostic marker for atherosclerotic plaque burden?. Am. J. Hypertens. 16 (2003) 356-362
19. Takeuchi K., Zhang B., Ideishi M., Urata H., Noda K., Tashiro T., et al. Influence of age and hypertension on the association between small artery compliance and coronary artery disease. Am. J. Hypertens. 17 (2004) 1188-1191
20. Stocker D.J., Taylor A.J., Langley R.W., Jezior M.R., and Vigersky R.A. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am. Heart J. 153 3 (2007) 445.e1-6
21. Meaney E., Vela A., Samaniego V., Meaney A., Asbún J., Zempoalteca J.C., et al. Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. Clin. Exp. Pharmacol. Physiol. 35 8 (2008) 895-903
22. Cusi K., and DeFronzo R.A. Metformin: a review of its metabolic effects. Diabetes Rev. 6 (1998) 89-131
23. Bennett S.M., Agrawal A., Elasha H., Heise M., Jones N.P., Walker M., et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet. Med. 21 (2004) 415-422
24. Nass C.M., and Blumenthal R.S. Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease. Am. J. Manag. Care 6 (2000) S1247-S1256
25. Freed M.I., Ratner R., Marcovina S.M., Kreider M.M., Biswas N., Cohen B.R., et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Rosiglitazone Study 108 investigators. Am. J. Cardiol. 90 (2002) 947-952
26. van Dijk R.A., Bakker S.J., Scheffer P.G., Heine R.J., and Stehouwer C.D. Associations of metabolic variables with arterial stiffness in type 2 diabetes mellitus: focus on insulin sensitivity and postprandial triglyceridaemia. Eur. J. Clin. Invest. 33 4 (2003) 307-315
27. Jacob M.P. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed. Pharmacother. 57 (2003) 195-202
28. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 6 (2002) 679-684
29. Goldstein B.J., Weissman P.N., Wooddell M.J., Waterhouse B.R., and Cobitz A.R. Reductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-study. Curr. Med. Res. Opin. 22 9 (2006) 1715-1723
30. Huang Z., Lei M.X., Liu L., and Tang Q.B. Effects of rosiglitazone on the IMTc and serum MMP-9 levels in newly diagnosed type 2 diabetic patients. Zhong Nan Da Xue Xue Bao Yi Xue Ban 31 3 (2006) 367-372
31. Ersoy C., Kiyici S., Budak F., Oral B., Guclu M., Duran C., et al. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Diabetes Res. Clin. Pract. 81 1 (2008) 56-60
32. Esposito K., Nappo F., Marfella R., Giugliano C., Giugliano F., Ciotola M., et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106 16 (2002) 2067-2072
33. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., et al. Evidence for a potent anti-inflammatory effect of rosiglitazone. J. Clin. Endocrinol. Metab. 89 (2004) 2728-2735
34. Wautier J.L., Boulanger E., and Wautier M.P. Postprandial hyperglycemia alters inflammatory and hemostatic parameters. Diabetes Metab. 32 (2006) 34-36
35. Nelken N.A., Coughlin S.R., Gordon D., and Wilcox J.N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J. Clin. Invest. 88 4 (1991) 1121-1127